EPS for BioTelemetry, Inc. (BEAT) Expected At $0.31

October 13, 2018 - By Hazel Jackson

BioTelemetry, Inc. (NASDAQ:BEAT) LogoInvestors sentiment decreased to 1.04 in Q2 2018. Its down 0.34, from 1.38 in 2018Q1. It dived, as 12 investors sold BioTelemetry, Inc. shares while 80 reduced holdings. 39 funds opened positions while 57 raised stakes. 29.62 million shares or 0.63% more from 29.44 million shares in 2018Q1 were reported.
Curbstone Financial Mngmt holds 0.31% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT) for 25,280 shares. Commonwealth Of Pennsylvania School Empls Retrmt Systems invested in 0% or 6,590 shares. Citigroup Inc reported 0% stake. Fiera Capital Corp invested in 126,185 shares or 0.02% of the stock. Summit Creek Advsr Limited Liability invested in 266,202 shares. California Pub Employees Retirement Sys stated it has 0% in BioTelemetry, Inc. (NASDAQ:BEAT). Piedmont Invest Advsr Ltd Liability Com reported 7,283 shares. Miles Cap Inc reported 9,177 shares or 0.25% of all its holdings. Vanguard, a Pennsylvania-based fund reported 1.85M shares. Public Sector Pension Investment Board accumulated 0.01% or 20,037 shares. Comerica Savings Bank holds 0.01% or 35,585 shares. State Common Retirement Fund stated it has 0.01% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT). Harvest Cap Strategies Lc reported 1.76% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT). Telemus Capital Limited Co accumulated 0.04% or 11,124 shares. Ancora Ltd Liability Corp owns 0.47% invested in BioTelemetry, Inc. (NASDAQ:BEAT) for 238,845 shares.

Analysts expect BioTelemetry, Inc. (NASDAQ:BEAT) to report $0.31 EPS on November, 6.They anticipate $0.15 EPS change or 93.75 % from last quarter’s $0.16 EPS. BEAT’s profit would be $10.14M giving it 42.99 P/E if the $0.31 EPS is correct. After having $0.46 EPS previously, BioTelemetry, Inc.’s analysts see -32.61 % EPS growth. The stock increased 2.97% or $1.54 during the last trading session, reaching $53.31. About 446,567 shares traded or 1.40% up from the average. BioTelemetry, Inc. (NASDAQ:BEAT) has risen 55.22% since October 13, 2017 and is uptrending. It has outperformed by 39.60% the S&P500.

BioTelemetry, Inc. (NASDAQ:BEAT) Ratings Coverage

Among 2 analysts covering BioTelemetry (NASDAQ:BEAT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioTelemetry had 2 analyst reports since June 20, 2018 according to SRatingsIntel. The firm earned “Outperform” rating on Friday, September 14 by Raymond James.

BioTelemetry, Inc. provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The company has market cap of $1.74 billion. The firm operates in three divisions: Healthcare, Research, and Technology. It currently has negative earnings. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders.

BioTelemetry, Inc. (NASDAQ:BEAT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>